Amgen have acquired KAI Pharmaceuticals for $315 million in cash which has given them rights to the experimental treatment for chronic kidney disease.
The kidney drug, called KAI-4169 is in Phase II and is being researched for the treatment of secondary hyperparathyroidism (SHPT) in those patients who are suffering with chronic kidney disease and are on dialysis. It is a drug that is administered intravenously.
The world’s largest biotech company, Amgen has given a loan to KAI to enable the Phase III trials to take place. The acquisition of KAI Pharmaceuticals will add to their already established dialysis drug portfolio (if it is approved). Amgen already have a drug used for the treatment of SHPT called Sensipar which is an oral drug.
Are you looking for a job in the Biotechnology Industry? Click here to search our current Biotech jobs online now.